| 1. |
- Glasbey, JC, et al.
(författare)
-
- 2021
-
swepub:Mat__t
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Sloot, Frea, et al.
(författare)
-
Inventory of current EU paediatric vision and hearing screening programmes
- 2015
-
Ingår i: Journal of Medical Screening. - : SAGE Publications. - 0969-1413 .- 1475-5793. ; 22:2, s. 55-64
-
Tidskriftsartikel (refereegranskat)abstract
- Objective: To examine the diversity in paediatric vision and hearing screening programmes in Europe. Methods: Themes for comparison of screening programmes derived from literature were used to compile three questionnaires on vision, hearing, and public health screening. Tests used, professions involved, age, and frequency of testing seem to influence sensitivity, specificity, and costs most. Questionnaires were sent to ophthalmologists, orthoptists, otolaryngologists, and audiologists involved in paediatric screening in all EU full-member, candidate, and associate states. Answers were cross-checked. Results: Thirty-nine countries participated; 35 have a vision screening programme, 33 a nation-wide neonatal hearing screening programme. Visual acuity (VA) is measured in 35 countries, in 71% of these more than once. First measurement of VA varies from three to seven years of age, but is usually before age five. At age three and four, picture charts, including Lea Hyvarinen, are used most; in children over four, Tumbling-E and Snellen. As first hearing screening test, otoacoustic emission is used most in healthy neonates, and auditory brainstem response in premature newborns. The majority of hearing testing programmes are staged; children are referred after 1–4 abnormal tests. Vision screening is performed mostly by paediatricians, ophthalmologists, or nurses. Funding is mostly by health insurance or state. Coverage was reported as >95% in half of countries, but reporting was often not first-hand. Conclusion: Largest differences were found in VA charts used (12), professions involved in vision screening (10), number of hearing screening tests before referral (1–4), and funding sources (8).
|
|
| 5. |
- Kehoe, Laura, et al.
(författare)
-
Make EU trade with Brazil sustainable
- 2019
-
Ingår i: Science. - : American Association for the Advancement of Science (AAAS). - 0036-8075 .- 1095-9203. ; 364:6438, s. 341-
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)
|
|
| 6. |
|
|
| 7. |
- De Benedictis, A., et al.
(författare)
-
Digital Twins for Anomaly Detection in the Industrial Internet of Things : Conceptual Architecture and Proof-of-Concept
- 2023
-
Ingår i: IEEE Transactions on Industrial Informatics. - : IEEE Computer Society. - 1551-3203 .- 1941-0050. ; 19:12, s. 11553-11563
-
Tidskriftsartikel (refereegranskat)abstract
- Modern cyber-physical systems based on the industrial Internet of Things (IIoT) can be highly distributed and heterogeneous, and that increases the risk of failures due to misbehavior of interconnected components, or other interaction anomalies. In this article, we introduce a conceptual architecture for IIoT anomaly detection based on the paradigms of digital twins (DT) and autonomic computing (AC), and we test it through a proof-of-concept of industrial relevance. The architecture is derived from the current state-of-the-art in DT research and leverages on the MAPE-K feedback loop of AC in order to monitor, analyze, plan, and execute appropriate reconfiguration or mitigation strategies based on the detected deviation from prescriptive behavior stored as shared knowledge. We demonstrate the approach and discuss results by using a reference operational scenario of adequate complexity and criticality within the European Railway Traffic Management System.
|
|
| 8. |
|
|
| 9. |
|
|
| 10. |
- Kubica, Jacek, et al.
(författare)
-
Prolonged antithrombotic therapy in patients after acute coronary syndrome : A critical appraisal of current European Society of Cardiology guidelines
- 2020
-
Ingår i: CARDIOLOGY JOURNAL. - : VM Media SP. zo.o VM Group SK. - 1897-5593 .- 1898-018X. ; 27:6, s. 661-676
-
Tidskriftsartikel (refereegranskat)abstract
- The increased risk of non-cardiovascular death in patients receiving clopidogrel or prasugrel in comparison with the placebo group in the Dual Antiplatelet Therapy (DAPT) trial in contrast to the decreased risk of cardiovascular death and all-cause death seen in patients treated with low-dose ticagrelor in the EU label population of the PEGASUS-TIMI 54 trial, resulted in inclusion in the 2020 ESC NSTE-ACS guidelines the recommendation for use of clopidogrel or prasugrel only if the patient is not eligible for treatment with ticagrelor. The prevalence of the primary outcome composed of cardiovascular death, stroke, or myocardial infarction was lower in the low-dose rivaroxaban and acetylsalicylic acid (ASA) group than in the ASA-alone group in the COMPASS trial. Moreover, all-cause mortality and cardiovascular mortality rates were lower in the rivaroxaban-plus-ASA group. Comparison of the PEGASUS-TIMI 54 and COMPASS trial patient characteristics clearly shows that each of these treatment strategies should be addressed at different groups of patients. A greater benefit in post-acute coronary syndrome (ACS) patients with a high risk of ischemic events and without high bleeding risk may be expected with ASA and ticagrelor 60 mg b.i.d. when the therapy is continued without interruption or with short interruption only after ACS. On the other hand, ASA and rivaroxaban 2.5 mg b.i.d. seems to be a better option when indications for dual antithrombotic therapy (DATT) appear after a longer time from ACS (more than 2 years) and/or from cessation of DAPT (more than 1 year) and in patients with multiple vascular bed atherosclerosis. Thus, both options of DATTs complement each other rather than compete, as can be presumed from the recommendations. However, a direct comparison between these strategies should be tested in future clinical trials.
|
|
| 11. |
- Meijers, Wouter C., et al.
(författare)
-
Biomarkers and low risk in heart failure. Data from COACH and TRIUMPH
- 2015
-
Ingår i: European Journal of Heart Failure. - : WILEY-BLACKWELL. - 1388-9842 .- 1879-0844. ; 17:12, s. 1271-1282
-
Tidskriftsartikel (refereegranskat)abstract
- AimTraditionally, risk stratification in heart failure (HF) emphasizes assessment of high risk. We aimed to determine if biomarkers could identify patients with HF at low risk for death or HF rehospitalization. Methods and resultsThis analysis was a substudy of The Coordinating Study Evaluating Outcomes of Advising and Counselling in Heart Failure (COACH) trial. Enrolment of HF patients occurred before discharge. We defined low risk as the absence of death and/or HF rehospitalizations at 180days. We tested a diverse group of 29 biomarkers on top of a clinical risk model, with and without N-terminal pro-B-type natriuretic peptide (NT-proBNP), and defined the low risk biomarker cut-off at the 10th percentile associated with high positive predictive value. The best performing biomarkers together with NT-proBNP and cardiac troponin I (cTnI) were re-evaluated in a validation cohort of 285 HF patients. Of 592 eligible COACH patients, the mean (SD) age was 71 (+/- 11) years and median (IQR) NT-proBNP was 2521 (1301-5634) pg/mL. Logistic regression analysis showed that only galectin-3, fully adjusted, was significantly associated with the absence of events at 180days (OR 8.1, 95% confidence interval 1.06-50.0, P=0.039). Galectin-3, showed incremental value when added to the clinical risk model without NT-proBNP (increase in area under the curve from 0.712 to 0.745, P=0.04). However, no biomarker showed significant improvement by net reclassification improvement on top of the clinical risk model, with or without NT-proBNP. We confirmed our results regarding galectin-3, NT-proBNP, and cTnI in the independent validation cohort. Conclusion We describe the value of various biomarkers to define low risk, and demonstrate that galectin-3 identifies HF patients at (very) low risk for 30-day and 180-day mortality and HF rehospitalizations after an episode of acute HF. Such patients might be safely discharged.
|
|
| 12. |
- Palialexis, A., et al.
(författare)
-
Monitoring biodiversity for the EU Marine Strategy Framework Directive: Lessons learnt from evaluating the official reports
- 2021
-
Ingår i: Marine Policy. - : Elsevier BV. - 0308-597X. ; 128
-
Tidskriftsartikel (refereegranskat)abstract
- Evaluating environmental policies creates opportunities for harmonising and refining their implementation using a heuristic approach, and considering the knowledge gaps in understanding the complex environmental processes. The European Union's (EU) Marine Strategy Framework Directive (MSFD) is an ambitious legislation that brings together state, pressure, and impact Descriptors of the marine environment, and is built on an ecosystem-based approach to management. Ultimately, the Directive aims to achieve Good Environmental Status (GES) and sustainable use of marine resources. The EU Member States’ (MS) reporting obligations for biodiversity monitoring were evaluated, to produce the first EU-wide overview of how monitoring programmes across EU waters are organised. Marine biodiversity monitoring is essential for the management of anthropogenic activities that affect the state of marine ecosystems, to support the understanding of complex marine systems, to determine GES, and to evaluate the effectiveness of the established measures. The EU MS put great effort into adapting their established biodiversity monitoring activities for the existing policy requirements, and to plan new monitoring programmes from the emerging needs of this ambitious policy. The monitoring reports provide a unique source of information, and this evaluation could lead to improve MS’ reporting, and harmonise implementation of the policy. Moreover, the evaluation provides a basis for sharing good practices, innovative monitoring standards, and developing joint monitoring programmes that could greatly facilitate the establishment of cost-efficient and accurate monitoring. As such, the recommendations from this policy evaluation could be relevant to any environmental management framework worldwide. © 2021 The Authors
|
|
| 13. |
- Ripepi, Vincenzo, et al.
(författare)
-
The VMC survey - XLVIII. Classical cepheids unveil the 3D geometry of the LMC
- 2022
-
Ingår i: Monthly Notices of the Royal Astronomical Society. - : Oxford University Press (OUP). - 0035-8711 .- 1365-2966. ; 512:1, s. 563-582
-
Tidskriftsartikel (refereegranskat)abstract
- We employed the VISTA near-infrared YJKssurvey of the Magellanic System (VMC) to analyse the Y, J, and Ks light curves of δCepheid stars (DCEPs) in the Large Magellanic Cloud (LMC). Our sample consists of 4408 objects accounting for 97 per cent of the combined list of OGLE IV and Gaia DR2 DCEPs. We determined a variety of period-luminosity (PL) and period-Wesenheit PW relationships for Fundamental (F) and First Overtone (1O) pulsators. We discovered for the first time a break in these relationships for 1O DCEPs at P= 0.58 d. We derived relative individual distances for DCEPs in the LMC with a precision of ∼1 kpc, calculating the position angle of the line of nodes and inclination of the galaxy: θ = 145.6 ± 1.0 deg and i = 25.7 ± 0.4 deg. The bar and the disc are seen under different viewing angles. We calculated the ages of the pulsators, finding two main episodes of DCEP formation lasting ∼40 Myr which happened 93 and 159 Myr ago. Likely as a result of its past interactions with the SMC, the LMC shows a non-planar distribution, with considerable structuring: the bar is divided into two distinct portions, the eastern and the western displaced by more than 1 kpc from each other. Similar behaviour is shown by the spiral arms. The LMC disc appears 'flared' and thick, with a disc scale height of h ∼0.97 kpc. This feature can be explained by strong tidal interactions with the Milky Way and/or the Small Magellanic Cloud or past merging events with now disrupted LMC satellites.
|
|
